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Background: Anemia is the most frequent hematological complica-
tion of lung cancer, particularly in advanced stages. The efﬁcacy of 
epoetin beta (E) is well documented in clinical trials in cancer patients 
(pts) with chemotherapy-induced anemia. This study was conducted to 
assess E use, efﬁcacy, safety and effect on quality of life in cancer pts, 
in usual practice. 
Methods: This prospective, multicenter, longitudinal, observational 
French study assessed a 4-month follow-up of informed pts with solid 
tumor or non myeloid hematological cancer treated with E for chemo-
therapy-related anemia. Data were collected between January 2005 and 
March 2006. Here we focus speciﬁcally on the subgroup of patients 
with lung cancer.
Results: Among 3200 pts enrolled by 423 specialists, 2810 were 
analysed. The most frequent cancer type was lung cancer with 622 pts 
(22% of all pts). Lung cancer pts’ characteristics were: mean age 63±10 
yrs, male 75%, performance status 0 (11%), 1 (48%), ≥2 (41%). TNM 
stages Ia-IIb: 7%, IIIa: 13%, IIIb: 17% and IV: 64%. The median time 
from disease diagnosis to inclusion was 2.7 months. 19% of pts were 
in relapse (median time to relapse: 2 months). 79% of H pts received 
platinum based regimen. 40% of pts received at least one cycle of 
chemotherapy before inclusion. 23% of pts received an anterior 
radiotherapy and 13% of pts had an associated radiotherapy with ongo-
ing chemotherapy. At inclusion, the mean of hemoglobin level was 
10.1±1.1 g/dl and 79% of pts had Hb level < 11 g/dl.
At initiation, pts received a median dose of 30000 U/week of E on a 
once weekly regimen schedule for 96% of pts. E was associated with 
iron supplementation in 62% of pts, and with blood transfusion in 4% 
pts.
Conclusion: These preliminary results describe baseline characteristics 
of lung cancer patients treated with epoetin beta. Final analyses includ-
ing hemoglobin and quality of life evolution under E treatment will be 
presented. In addition, predictive factors of response to E treatment will 
be analyzed.
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Background: JMTO LC00-03, a randomized trial of VGD versus PC 
in patients with advanced NSCLC (2001-2005), showed differences 
between the two treatment groups in response rate (25 vs 37.1%) and 
regimens speciﬁc toxicities including taxane-related toxicities such 
as numbness (0 vs 16.2%) and neuropathy (0.5 vs 9.6%), but not in 
overall survival (MST: 13.6 vs 14.1 mos) and progression-free survival 
(MST: 5.5 vs 5.8 mos). (Kawahara et al, # 7013, ASCO, 2006).
Methods: Patients with advanced NSCLC who were randomly as-
signed to VGD or PC (JMTO LC00-03) were asked to enter this QOL 
study since 2004. After the informed consent, the patients themselves 
assessed Functional Assessment of Cancer Therapy- FACT-L, FACT-
Taxane and FACIT-SP score in baseline, and at 6-, 12-, 18-weeks after 
the treatment. The assessment results were not informed to the partici-
pating physicians. The primary endpoint was the comparison of total 
score of QOL in each assessment between the 2 arms. The longitudinal 
analysis was used to compare mean changes of the QOL score over the 
two treatment groups. 
Results: Eighty-four patients entered this study. Sixty-eight patients 
from the trial (VGD: 34, PC: 34) who submitted both baseline ques-
tionnaire and at least one questionnaire over the course of the treatment 
were eligible. The longitudinal analysis showed signiﬁcant difference 
in the mean score of FACT-Taxane (p<0.001) in the treatment over 
time, but no signiﬁcant differences in the FACT-L score (p=0.261) and 
FACIT-SP (p=0.207). 
Conclusions: There were no statistically signiﬁcant differences in 
FACT-L and FACIT-SP score between the two groups. However, there 
was a signiﬁcant difference in FACT-Taxane score favoring VGD. This 
may be due to the difference in frequency of neuropathy with docetaxel 
than with paclitaxel.
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Background: About 30-40% of lung cancer patients have skeletal me-
tastasis and about half of them experience skeletal related events(SREs; 
bone pain, spinal cord compression, pathologic fracture, radiation 
therapy to bone, bone surgery). Zoledronic acid has potent anti-resorp-
tive properties on bone metabolism. In addition, it has an anti-neoplas-
tic effect on cancer cell. In a randomized controlled trial, zoledronic 
acid reduced the incidence of SREs and delayed the time to ﬁrst SRE in 
patients with skeletal metastasis from lung and other solid tumors. 
Methods: From October 2003, 132 lung cancer patients with bone 
metastasis have been observed for the incidence of SREs and time to 
ﬁrst SRE. Fifty-two patients (Treatment group, TG) were treated with 
zoledronic acid (4mg 3weekly) and the remaining 80 patients (Control 
group, CG) did not receive zoledronic acid. 
Results: Treatment of zoledronic acid ranged from 1 to 13 cycles 
(mean=9.5 cycles). Fifty-three(40.2%) patients experienced SREs; ra-
diation therapy(33), spinal cord compression(4), pathologic fracture(6), 
bone surgery(2), bone pain(15). The incidence of SREs was not sig-
niﬁcantly different between TG(32.7% 17/52) and CG(45.0%, 36/80, 
p=0.2). Median time to ﬁrst SRE was 289 days (95% CI; 152~426 
days) in 132 patients, and no signiﬁcant difference between the two 
groups was observed. 
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Conclusions: We could observe a tendency of fewer SREs in TG com-
pared to CG. More patients will be needed to get statistically signiﬁcant 
differences according to treatment arms.
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Introduction: Euthanasia has taken its place again in discussion 
agenda after the legal arrangements permitting active euthanasia in the 
Netherlands and Belgium were made. Physicians’ views, especially of 
those working in the ﬁeld of oncology, are very important in revealing 
the views on euthanasia. Our study was conducted to show the ap-
proach of the pulmonologists heavily working in the ﬁeld of oncology 
in Turkey.
Materials and Methods: In our survey study, 110 physicians working 
in pulmonary medicine in Turkey were accessed, and the data were as-
sessed By SPSS program.
Results: The mean age of the pulmonologists participating in our study 
was 32.90±7.01 years, and 40.8 % of these stated not being against 
euthanasia. Of the participants, 22.7 % stated encountering “ wish 
for euthanasia”, and 46.7 % stated believing that euthanasia is being 
performed hiddenly though for bidden.
Conclusion: The views on euthanasia and patient rights of the physi-
cians attending terminal-stage patients are very important. The partici-
pating physicians frequently encountering “wish for euthanasia” and 
their extensive beliefs about that euthanasia is being performed hid-
denly shows this issue should absolutely be discussed in our country.
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Background: Previous studies have shown that antibacterial prophy-
laxis after cytotoxic chemotherapy reduces the incidence of febrile 
episode and infection. However the role of prophylactic antibacterial 
agents after chemotherapy remains controversial. The meaning of fe-
brile episode and infection is vague as outcome variable after cytotoxic 
chemotherapy, but pneumonia in lung cancer after cytotoxic chemo-
therapy can bring life-threatening consequences on patients.
The purpose of this study is to demonstrate the prevalence and risk 
factors of pneumonia after cytotoxic chemotherapy in advanced lung 
cancer patients.
Methods: 229 patients took cytotoxic chemotherapy in Seoul National 
University Hospital for advanced lung cancer progressed during a year 
2005, and 12 patients who took prophylactic antibiotics were excluded 
from this study. Therefore 217 patients were retrospectively analyzed.
Those patients, who had not taken chemotherapy or radiation therapy 
previously with ECOG performance status 0-2, stage III or IV NSCLCa 
and SCLCa, were eligible for this study. Pneumonia after chemo-
therapy was deﬁned as pneumonia which developed after ﬁrst cycle of 
ﬁrst line chemotherapy. Risk factors such as age, sex, ECOG perfor-
mance status, pathological diagnosis, stage of disease, smoking, COPD 
(FEV1/FVC less than 70%), tumor position and pneumonia history 
were analyzed.
Results: The mean age was 61 years (range, 31-85). The number of 
male patients were 171 (79%), and ECOG 2 patients were 40 (18%). 
COPD patients constituted 18% (40 patients) out of all the patients.
Pneumonia occurred in 10 patients (4%) out of 217 after cytotoxic che-
motherapy, and the occurrence rate was signiﬁcantly higher in COPD 
patients, compared to non-COPD patients (13% vs 3%, P=0.02), and 
also higher in patients with ECOG 2 compared to those with ECOG 
0~1 (10% vs 3%, P=0.09). One patient out of ten with pneumonia died 
from sepsis, the other one could not received further cytotoxic chemo-
therapy.
Twelve patients had taken antibacterial prophylaxis after pneumonia 
before chemotherapy, and a pneumonia developed in one patient (8%) 
after chemotherapy. Four patients hadn’t taken antibacterial prophy-
laxis after outbreak of pneumonia, and the one among 4 of them (25%) 
had developed into pneumonia.
Conclusions: This study demonstrated that the patients with COPD, 
deﬁned as FEV1/FVC less than 70% and the ones with poor perfor-
mance signiﬁcantly showed higher incidence of pneumonia.
A prospective study is required to verify the risk factors that affect in-
cidence of pneumonia after cytotoxic chemotherapy, and to clarify the 
effect of antibacterial prophylaxis on patients in high risk.
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Introduction: In 1980, Dewys WD et al. (Am J Med 1980;69:491-7) 
have demonstrated a high prevalence of malnutrition in cancer patients, 
including lung cancer. The aim of the present study was to re-evaluate, 
25 years later, the prevalence of malnutrition in a non selected popula-
tion of cancer patients and also the nutritional support to these patients.
Methods: A prospective one-day prevalence survey was carried out 
in 154 wards of private or public hospitals in 24 cities in France. 
Height, actual and usual body weight were systematically assessed 
in outpatients and inpatients who were present that day. Malnutrition 
was deﬁned as a BMI≤18.5 (for 18-74 aged patients) or BMI≤21 (for 
patients of 75 years or more) and/or a loss of body weight ≥ 10% from 
the beginning of the disease.
Results: 2,068 patients (1,189 men and 879 women) aged 59.3 ± 13.6 
years were evaluated and nutritional status was available in 1,903 
patients: 247 patients had lung cancer (72% of inpatients and 28% of 
outpatients); 1821 patients had head and neck, leukemia/lymphoma, 
colon/rectum, stomach, oesophagus, pancreas, breast, ovary/uterus, 
prostate cancer. Lung cancer was local in 9% of patients, loco-regional 
in 25% and metastatic in 66%. Within lung cancer patients, 89% of 
